Executive Summary
Real-world LAMPOON data from the STS/ACC TVT Registry show the transcatheter mitral leaflet-splitting technique prevents LVOT obstruction in 95.5% of cases, but 30-day mortality after valve-in-MAC procedures ran to 23.7% versus 6.1% for valve-in-ring — a signal that TMVR in native calcified valves remains a salvage operation, not a democratized therapy. CMS added a proposed TAVR coverage framework, Jenscare's LuX-Valve Plus captured a EU MDR CE mark, and Medtronic recalled a heart valve delivery system — tightening the case for center-of-excellence regionalization over broad diffusion.
- LAMPOON is now performed at 29.2% of US TMVR sites (8.9% of 9,250 cases), with 61 sites reporting only a single case — volume-outcome relationships remain unstudied (TCTMD).
- Jenscare's LuX-Valve Plus earns CE mark for transcatheter tricuspid replacement, entering a European market where ESC 2025 rates transcatheter TV therapy Class IIa (TradingView).
- Laplace Interventional registered a 700-patient pivotal TTVR trial with Edwards EVOQUE as active comparator — the first head-to-head in the tricuspid replacement space (NCT07687485).
- Mechanical leaflet splitting for valve-in-valve TAVR is feasible in high-risk patients with degenerated bioprostheses at risk of coronary obstruction (ACC).
- Medtronic issued a safety-risk recall on a heart valve delivery system, adding to ongoing durability and delivery-platform scrutiny across TAVR (Cardiovascular Business).
What to watch: Edwards Lifesciences reports Q2 earnings July 29 — the first read on structural heart momentum since the LAMPOON registry and TTVR pivotal announcements landed.
Aortic Valve (TAVR/TAVI)
Coronary access, not durability, drove today's aortic file. A new ACC series on mechanical leaflet splitting in valve-in-valve TAVR reports feasibility in high-risk patients with degenerated surgical bioprostheses at risk of sinus sequestration — the exact anatomy the ESC 2025 flags in its expanded lifetime-management framework. A separate JACC Case Reports description of Evolut FX+ commissural alignment in a patient with a single coronary artery reinforces the same point: as TAVR expands into younger and anatomically complex patients, the index-procedure decision must plan for the next intervention. Both are case-level descriptions, not comparative data. ACC/AHA 2020 still favors SAVR under 65 on durability grounds, and ESC 2025 draws its SAVR-preferred line at 70 — neither guideline is moved by feasibility case series. Two JACC Asia editorials (PAPi after TAVR, right heart catheterization in the modern TAVR era) argue that pulmonary hemodynamics and RV function need to re-enter pre-TAVR risk assessment — a message that dovetails with the ESC's push toward integrated global cardiac damage staging. Separately, CMS has proposed a revised TAVR coverage framework, details of which will bear directly on volume distribution across US sites.
Mitral Valve (MitraClip, PASCAL, TMVR)
The LAMPOON real-world data are the most consequential mitral read of the year so far. The STS/ACC TVT Registry analysis of 9,250 TMVR procedures at 569 US sites shows LAMPOON prevented LVOT obstruction in 95.5% of cases — a genuine technical win. The mortality distribution is where the story lives: [NOTABLE] 30-day death was 23.7% in valve-in-MAC, 8.3% in valve-in-valve, and 6.1% in valve-in-ring, with 1-year native-valve mortality exceeding 40%. Sixty-one of the participating sites performed a single LAMPOON case. The discussants — Villablanca, Whisenant, Adams — converged on one conclusion: this is not a technique to democratize. This is registry data (non-randomized, LAMPOON reporting optional in the drop-down), so the true denominator is likely higher and outcomes may be biased toward reporting sites. Surgical mitral repair remains Class I in both ACC/AHA 2020 and ESC 2025 for primary MR when feasible; the ESC's expanded Class I indication for asymptomatic patients with adverse features (AF, SPAP >50, LAVI >=60, TR) further widens the surgical repair pool. TMVR in MAC is not — and today's data confirm should not be — a routine alternative to surgery in operable patients.
Tricuspid Valve (TriClip, TTVR)
The tricuspid replacement space just went competitive. Laplace Interventional registered a 700-patient pivotal TTVR trial (NCT07687485) with the Edwards EVOQUE system as active comparator — the first head-to-head between transcatheter tricuspid replacement platforms. Simultaneously, Jenscare's LuX-Valve Plus obtained EU MDR CE certification, opening a second European commercial pathway. ESC 2025 rates transcatheter TV treatment Class IIa (LOE A) based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — a leap from the ACC/AHA 2020's silence on the topic. Surgical TV replacement in isolated form carries historically high mortality (8-20%), and ESC 2025 upgraded symptomatic primary TR surgery to Class I, underscoring that transcatheter TVR occupies the high-surgical-risk tier, not the broader symptomatic population. The TVT Registry EVOQUE readout published earlier this year showed technical success 98.4%, 30-day mortality 3.1%, and new pacemaker implantation in 15.9% of CIED-naive patients — better than TRISCEND II on pacemaker and bleeding rates, but a pacemaker burden that still separates transcatheter TVR from repair. The competitive question now: does LuX-Valve Plus differentiate on pacemaker rate or paravalvular leak? That is what the Laplace vs EVOQUE head-to-head will need to answer.
Surgical vs. Transcatheter Comparisons
No dedicated head-to-head trials reported today, but the LAMPOON real-world data function as an unintended comparison. When 1-year mortality after TMVR in a native calcified valve exceeds 40%, the surgical mitral replacement literature — even in high-MAC populations — becomes the relevant benchmark, not the ceiling. ACC/AHA 2020 and ESC 2025 both anchor mitral valve therapy on surgical repair as the durable standard; today's data reinforce that transcatheter mitral replacement remains an option for patients with no operable alternative, not for those who prefer to avoid sternotomy.
Device & Technology
Jenscare's LuX-Valve Plus CE mark is the day's largest device-approval event, opening a second European TTVR pathway alongside EVOQUE. Edwards continues to push its SAPIEN 3 Ultra positioning in the US market, and Medtronic recalled a heart valve delivery system for a safety issue — a reminder that platform reliability is a competitive variable, not a solved problem.
Regulatory & Policy
CMS has published a proposed TAVR coverage framework (details to be scrutinized in coming days). The direction of travel matters most: US TAVR reimbursement policy tends to reinforce center-volume thresholds and heart-team documentation. If the framework tightens either, expect the LAMPOON discussants' "center of excellence" argument to gain regulatory teeth.
Industry & Market
Structural heart remains a two-story market: durable clinical demand at the top of the funnel (aortic + tricuspid expansion), and complication-driven scrutiny at the platform level (Medtronic recall, LAMPOON mortality). Edwards commentary this week highlighted the breadth of the structural heart platform beyond a single procedure, and an SWOT-style investor case built on market share opportunity.
Financial Analysis
The market is separating structural heart pure-plays from diversified medtech in a way that reflects clinical exposure. Boston Scientific is down 53.95% over six months — a move that dwarfs the ~29% decline in the diversified Abbott — despite a strong-buy analyst consensus and a July 29 earnings print with a $5.37B revenue estimate. Anteris Technologies (AVR.AX) is up 92.37% on the six-month tape, riding investor enthusiasm for early-stage TAVR platforms even as the day's -7.71% move confirms the trade is crowded. Edwards Lifesciences insider Form 4 filings this week are routine tax-vesting withholding events, not directional signals. The larger financial question: if CMS's TAVR coverage framework tightens volume distribution, does that help the incumbents (Edwards, Medtronic) with existing high-volume site relationships, or does it slow procedural growth? The 5-year LANDMARK non-inferiority data for Myval versus SAPIEN/Evolut adds a competitive wedge that European payers will notice.
Valve Industry Stocks
Abbott (ABT)
- Close: $95.84 (+0.22% daily); 6-month change -23.18%
- Market cap: $166.9B; Trailing P/E 26.85; Forward P/E 15.83; Beta 0.61
- 52-week range: $81.97 – $137.49
- Analyst target: $116.40 (25 analysts); consensus: buy
- Next earnings: July 16 (EPS est $1.28; Rev est $12.52B)
- Commentary: The MitraClip and TriClip franchises face rising ESC-driven tailwinds (Class I for ventricular SMR TEER; Class IIa for transcatheter TV) but a challenging broader medtech tape has compressed the multiple.
Boston Scientific (BSX)
- Close: $45.30 (+1.57% daily); 6-month change -53.95%
- Market cap: $67.3B; Trailing P/E 18.64; Forward P/E 12.19; Beta 0.58
- 52-week range: $42.25 – $109.50
- Analyst target: $74.55 (29 analysts); consensus: strong buy
- Next earnings: July 29 (EPS est $0.83; Rev est $5.37B)
- Commentary: The gap between an $84 analyst target midpoint and a $45 tape is now the largest disconnect in structural heart. The July 29 print will test whether the sell-off reflects a fundamental deceleration or a positioning washout.
Anteris Technologies (AVR.AX)
- Close: A$14.12 (-7.71% daily); 6-month change +92.37%
- Market cap: A$1.4B; Forward P/E -6.48; Beta 0.73
- 52-week range: A$4.68 – A$15.47
- Analyst target: A$13.00 (1 analyst); consensus: none
- Commentary: DurAVR next-generation TAVR narrative continues to drive the momentum trade. Sparse analyst coverage means single-day moves can be violent — as today's 7.71% drop from an all-time high demonstrates.
Market outlook: Structural heart continues to bifurcate. Pure-play developers with pipeline optionality (Anteris) trade on narrative; diversified incumbents (Abbott, Boston Scientific) trade on quarterly execution. The Edwards earnings print on July 29 will set the tone for the sector's second half.
Clinical Trial Updates
Tricuspid Replacement
- [LANDMARK] NCT07687485 — Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System. Status: Not Yet Recruiting. Phase: NA. Enrollment: 700. Sponsor: Laplace Interventional. Interventions: Laplace TTVR vs Edwards EVOQUE. Significance: First registered head-to-head TTVR platform comparison. The trial design puts EVOQUE — already commercially available and analyzed in the TVT Registry — in the position of active comparator. Outcomes on pacemaker rate and paravalvular leak will define the second-generation TTVR competitive field.
Social & Conference Highlights
The LAMPOON discussion at New York Valves 2026 crystallized a shift in the mitral community: Villablanca, Whisenant, Zahr, and Adams all argued for center-of-excellence regionalization over technique democratization. Adams's remark — "we're going to have to have a little more regionalization of expertise and transparency for patients" — is the direction of travel.
Edwards's July 29 print will be read against the LAMPOON registry, the Medtronic recall, and CMS's coverage framework — three data points that collectively define whether structural heart's expansion enters a consolidation phase or a new growth leg.